Treatment of Congenital Hemophilia A and B
Publication Date: June 19, 2024
Key Points
Key Points
- Hemophilia is a congenital X-linked bleeding disorder that affects an estimated 1,125,000 individuals worldwide, 80% of whom have hemophilia A.
- Individuals with severe (and some moderate) forms of hemophilia not treated with prophylaxis may experience spontaneous bleeding, of which the most frequent are joint and muscle bleeding.
- Prophylaxis rather than episodic treatment is strongly recommended for severe and moderately-severe hemophilia A and B.
Treatment
...atment...
...hilia A Without Inhib...
...ls with severe and moderately-severe hemop...
...with severe and moderately-severe...
...duals with severe and moderately-severe hemophil...
...resource-limited settings in which the use of stan...
...eviously untreated individuals with severe...
...viduals with severe and moderately-...
...ia A With Inhibitors...
...ndividuals with severe hemophilia...
In individuals with severe hemophili...
...s with severe hemophilia A with hi...
...dividuals with severe hemophilia A...
...iduals with severe hemophilia A with inhibito...
...philia B Without Inhib...
...ith severe and moderately-severe hemophi...
...ith severe and moderately-severe hemophilia...